Skip to content

TRXB TREX BIO INC

Follow

Common Stock, $0.0001 par value (common), issuer CIK 2139097

Filings received so far for Q3 2026: 1 13F filer report a position in TRXB shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.

Insider trades

No Form 4 transaction on this security in the data.

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Transce3nd, LLC100$1.52K<0.01%new13F-HRTimeline

Events

  • Pfizer Inc and 1 other reporting person reported 1,965,066 TRXB shares, 7.2% of the class, as of 2026-10-08, in a 13G filed 2026-10-16. 0000078003-26-000118

    Accepted , ingested
  • ELI LILLY & Co reported 5,480,872 TRXB shares, 19.9% of the class, as of 2026-10-13, in a 13D filed 2026-10-16. 0000059478-26-000095

    Accepted , ingested
  • SV Biotech Crossover Opportunities Fund LP and 1 other reporting person reported 1,920,667 TRXB shares, 7% of the class, as of 2026-10-08, in a 13D filed 2026-10-16. 0001829126-26-011242

    Accepted , ingested
  • Johnson & Johnson Innovation - JJDC, Inc. and 1 other reporting person reported 1,475,302 TRXB shares, 5.3% of the class, as of 2026-10-13, in a 13G filed 2026-10-15. 0000904454-26-000517

    Accepted , ingested